SciELO - Scientific Electronic Library Online

 
vol.29 issue4High-Flow Nasal Cannula Oxygen Therapy in A Palliative Care Context at Home, a New Opportunity? A Palliative Care Team ExperienceMultisystem Inflammatory Syndrome-Adult: A Rare Presentation of Infection by SARS-CoV-2 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Medicina Interna

Print version ISSN 0872-671X

Abstract

ROCHA, Diana Isabel et al. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. Medicina Interna [online]. 2022, vol.29, n.4, pp.19-23.  Epub Jan 02, 2023. ISSN 0872-671X.  https://doi.org/10.24950/rspmi.227.

The first vaccines against the SARS-CoV-2 virus appea-red one year after the WHO declared COVID-19 as a pandemic, with data from United Kingdom and United States of America (USA) reporting a reduction in hospitalization about 67% e 94%, with one or two doses of an approved vaccine. In February 2021, the first cases of thrombocytopenia and thrombosis at uncommon sites (cerebral venous sinus and splanchnic venous thrombosis) induced by the vaccines were described. The incidence is still unknown, but early studies in the USA suggest an incidence of 1 in 533 333/vaccinated individuals, and this is probably underestimated. Although un-common, it is a serious adverse effect with a high mortality rate, estimated at 20%. This case report highlights the need for a high level of suspicion, which may change the prognosis of some of these patients.

Keywords : COVID-19 Vaccines/adverse effects; COVID-19/prevention & control; SARS-CoV-2; Venous Thrombosis; Thrombocytopenia/chemically induced..

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )